Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engert

Showing results (81-90 of 173) with videos related to

Pageof 18
Sort By:
European Journal of Medical Research|March 2, 2005
A randomized, placebo-controlled study of the use of filgrastim in non neutropenic patients with nosocomial pneumoniaPia Hartmann, J Lammertink, G Mansmann, et al.
Leukemia|April 14, 2000
A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemiaT Pfitzner, A Engert, H Wittor, et al.
Leukemia & Lymphoma|July 16, 2005
Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's diseaseL Smardova, A Engert, H Haverkamp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 1998
Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM)A Josting, I Kàtay, U Rueffer, et al.
British Journal of Cancer|July 20, 2000
Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panningA Klimka, B Matthey, R C Roovers, et al.
Blood|September 15, 1993
Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodiesH Bohlen, T Hopff, O Manzke, et al.
Cancer Research|January 1, 1990
Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's diseaseA Engert, F Burrows, W Jung, et al.
Leukemia & Lymphoma|August 1, 1995
Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomasK Fenchel, L Bergmann, P Wijermans, et al.
International Journal of Cancer|October 9, 1995
Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in miceA Engert, C Gottstein, H Bohlen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2008
Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trialsM Sieniawski, T Reineke, A Josting, et al.
Pageof 18

Showing results (81-90 of 173) with videos related to

Sort By:
Pageof 18
European Journal of Medical Research|March 2, 2005
A randomized, placebo-controlled study of the use of filgrastim in non neutropenic patients with nosocomial pneumoniaPia Hartmann, J Lammertink, G Mansmann, et al.
Leukemia|April 14, 2000
A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemiaT Pfitzner, A Engert, H Wittor, et al.
Leukemia & Lymphoma|July 16, 2005
Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's diseaseL Smardova, A Engert, H Haverkamp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 1998
Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM)A Josting, I Kàtay, U Rueffer, et al.
British Journal of Cancer|July 20, 2000
Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panningA Klimka, B Matthey, R C Roovers, et al.
Blood|September 15, 1993
Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodiesH Bohlen, T Hopff, O Manzke, et al.
Cancer Research|January 1, 1990
Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's diseaseA Engert, F Burrows, W Jung, et al.
Leukemia & Lymphoma|August 1, 1995
Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomasK Fenchel, L Bergmann, P Wijermans, et al.
International Journal of Cancer|October 9, 1995
Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in miceA Engert, C Gottstein, H Bohlen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2008
Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trialsM Sieniawski, T Reineke, A Josting, et al.
Pageof 18